Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LN-145 by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
LN-145 by Iovance Biotherapeutics for Ewing Sarcoma: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase...
LN-145 by Iovance Biotherapeutics for Primary CNS Lymphoma: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase I for Primary CNS Lymphoma. According to GlobalData,...
LN-145 by Iovance Biotherapeutics for Rhabdomyosarcoma: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...